To The Moon

From Lab Breakthrough to Market Reality When a biotech stock plummets 45% from its peak, most investors run for the hills. But in the peculiar world of biotechnology, such dramatic drops often present intriguing opportunities. CRISPR Therapeutics finds itself in precisely this position – a pioneer in gene-editing whose share price has taken a beating, yet Wall Street analysts are forecasting a potential 87% upside to $83.6. The question is: are we looking at a revolutionary medical powerhouse or just another promising science project that will burn through investor capital? Editing DNA and portfolios: CRISPR's dual revolution Casgevy: The Game-Changer Now in Play The approval of Casgevy represents far more than a regulatory milestone – it's CRISPR's transition from theoretical science to c

The reassessment of Chinese technology assets, initially triggered by breakthroughs in AI platforms like DeepSeek, continues to dominate market narratives. International capital remains bullish, with institutional investors increasingly drawing parallels between undervalued Chinese tech stocks and U.S. counterparts, sparking fresh debates about global valuation disparities. My positioned HS and HST ETF asset value increased. I trimmed some position of HST to lock profits. I got profits SGD 9.7K, or 2.18% in February.  As this month marks the annual report season, several of my strategically positioned dividend stocks have awakened from their seasonal slumber to claim their dividend rights.. I booked SGD 10K in declared dividends, with SGD 1.6K already received in 2025. Singapore and H